Understanding how cancer vaccines affect immune responses in lung cancer
Investigating Immune Responses to Neoantigen Cancer Vaccines using In Vivo Functionalized Lineage
This study is looking at ways to make cancer vaccines work better for people with lung cancer by understanding why some patients respond well to treatments while others don’t, which could help create more effective options for those who need them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11003274 on NIH RePORTER |
What this research studies
This research investigates how immune responses to cancer vaccines can be improved, particularly in lung cancer patients. By using advanced mouse models that mimic human lung cancer, the study aims to explore why some patients respond well to immune checkpoint inhibitors while others do not. The researchers will analyze the tumor's genetic makeup and its interaction with the immune system to identify potential mechanisms of resistance to treatment. This could lead to more effective therapies for patients who currently have limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients, particularly those who have not responded to existing immune checkpoint therapies.
Not a fit: Patients with early-stage lung cancer or those who have not been diagnosed with lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer vaccines that enhance immune responses in lung cancer patients, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promise in using immune checkpoint inhibitors for lung cancer, but this approach is novel in its use of advanced mouse models to better understand resistance mechanisms.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Robles-Oteiza, Camila — Dana-Farber Cancer Inst
- Study coordinator: Robles-Oteiza, Camila
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.